SUTRO BIOPHARMA INC
STRONASDAQTrading Snapshot
- Day Range
- $8.46 β $8.99
- 52-Week Range
- $7.15 β $43.85
- Volume (shares)
- 275,898
- Avg Volume (shares)
- β
- Shares Outstanding
- 16.6M
- Next Earnings
- 2027-03-22
Fundamentals Snapshot
- Annual Revenue
- $102M
- Last Q Revenue
- $9M
- P/E Ratio
- β
- P/S Ratio
- 3.1x
- EPS (TTM)
- $-17.32
- Dividend Yield
- β
- Dilution (1yr)
- +4.0%
SUTRO BIOPHARMA INC
STROAbout SUTRO BIOPHARMA INC
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
β STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 β

Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks
The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising ea

Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO),Β a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjug

Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround
Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings esti

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
β STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year β Β Β Β Β Β Β β Initial clinical data expected in the second half of 2027 β SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) --

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conju